Interleukin-1 (IL-1) is a growth arrest signal for diverse human tumor cell lines. We report here that the action of this cytokine in melanoma cells is associated with induction of EGR-1, a zinc finger protein that activates gene transcription. Both growth arrest and EGR-1 are induced via the type I receptor of IL-1. To determine the role of EGR-1 in IL-1 action in melanoma cells, we used a chimera expressing the transrepression domain of the Wilms' tumor gene, WT1, and the DNA binding domain of Egr-1. This chimera competitively inhibited EGR-1-dependent transactivation via the GC-rich DNA binding sequence, indicating that it acted as a functional dominant negative mutant of Egr-1. Melanoma cell lines stably transfected with the dominant negative mutant construct were supersensitive to IL-1 and showed accelerated G 0 /G 1 growth arrest compared with the parental cell line. The effect of the dominant negative mutant construct was mimicked by addition of an antisense Egr-1 oligomer to the culture medium of the parental cells: the oligomer inhibited EGR-1 expression and accelerated the growth-inhibitory response to IL-1. These data imply that EGR-1 acts to delay IL-1-mediated tumor growth arrest.
Interleukin-1 (IL-1) is a cytokine produced by activated macrophages and monocytes that plays diverse biological roles in the host system (16, 17, 27, 53) . This cytokine has been incriminated in a variety of adverse effects, exemplified by its involvement in various disease states in the host system (16, 17, 27, 53) . Interestingly, this cytokine is also involved in effects that are beneficial to the host, as exemplified by the recruitment of an immune response and growth inhibition of tumor cells (22, 25, 27, 31, 35, 40, 52, 55, 57) . Cultures of melanoma (22, 45, 48, 55, 57, 72) , breast carcinoma (15, 22) , myeloid leukemia (39, 52) , ovarian carcinoma (33) , and lung adenocarcinoma (24) cells are highly susceptible to IL-1-mediated growth arrest. A role for IL-1 in host defense against tumors is further suggested by the ability of the cytokine to augment in vitro natural killer cell activity (51) and monocyte-mediated tumor toxicity (53) and to induce tumor regression in mice (cited in reference 72) .
Two forms of IL-1 (␣ and ␤) have been identified as products of two separate genes (2, 44) , but they have similar biological effects (19, 34, 53) . The biological action of IL-1 is mediated by cell surface receptors on target cells (19, 34) . Two types of IL-1 receptors (IL-1Rs), IL-1R I and IL-1R II , have been identified. IL-1R I is an 80-kDa glycoprotein, preferentially expressed on fibroblasts and T cells (19, 20, 34, 65) , whereas IL-1R II is a 60-kDa glycoprotein present in B lymphocytes, monocytes, neutrophils, bone marrow, and hepatoma cells (5, 9, 30, 46, 61) . Of the two receptors, IL-1R I has been shown to be responsible for gene induction (64) . IL-1R II , on the other hand, is not involved in signal transduction; on the contrary, it may act as a decoy to dampen signaling via IL-1R I (13, 64) . The binding of IL-1 to its receptor results in activation of a variety of second-messenger signaling pathways (reviewed in reference 3) and immediate-early gene programs (55, 57) .
However, the precise functional role of the signaling cascades or genes in IL-1 action has not been elucidated.
Melanoma cell lines derived and established from primary tumors have been shown to be sensitive to IL-1-inducible growth inhibition (22, 41, 55, 57) . We are studying the gene program associated with IL-1 action in human melanoma A375-C6 cells (3, 55, 57) . The growth arrest action of IL-1 in these cells is dependent on early gene induction events (55) . To identify genes that may play key roles in the growth arrest action of IL-1, we performed differential screening on a cDNA library that was enriched for IL-1-inducible genes (55, 57) . This study led to the isolation of cDNAs representing genes that encode cytokines (GRO-␣ and GRO-␤) and transcription factors (c-JUN, NUR77/NAK-1, and IRG-9/TIS11) (55) . In the course of this work, one of the differentially expressed genes was identified as Egr-1 (also referred to as NGFI-A, zif268, Krox-24, and TIS8), a gene known to encode a zinc finger transcription factor (8, 11, 12, 36, 37, 38, 47, 67, 68) .
Egr-1 was originally identified as an immediate-early gene rapidly activated by serum in fibroblasts (68) and by nerve growth factor in PC12 cells (47, 67) . Subsequently, this gene was shown to be rapidly induced in response to growth factors, membrane depolarization, seizure, synaptic activity, ischemia, nerve injury, B-cell maturation, and differentiation of nerve, bone, and myeloid cells (reviewed in reference 66). The human Egr-1 gene has been localized to human chromosome 5, in a region that is known to be often deleted in patients suffering from therapy-induced acute myeloid leukemia (67) . The Egr-1 gene product, EGR-1, is a nuclear protein which contains three zinc fingers of the C 2 H 2 subtype (7, 26) . Structure-function analysis of EGR-1 protein suggests that the amino acids constituting the zinc finger motif confer DNA binding function, whereas the NH 2 -terminal amino acids confer transactivation function (26, 60) . EGR-1 belongs to the Egr family (66) of transcription factors, which includes EGR-2 (Krox-20 [8, 32, 56] ), EGR-3 (54) , NGFI-C (14) , and the tumor suppressor Wilms' tumor gene product, WT1 (6) . WT1 is deleted or mutated in Wilms' tumor, a renal cancer of children (29, 59) .
Transcription factors of the Egr family show high degree of conservation in the amino acids constituting the zinc finger domain and bind to the same GC-rich consensus DNA sequence, GCGGGGGCG (12, 21, 26, 42, 54, 58, 66) . EGR-1 has been shown to be a positive activator of transcription, whereas WT1 is a transcriptional repressor, both acting via binding to the same GC-rich consensus sequence in reporter constructs (21, 42) . However, EGR-1 has the ability to act as a positive or negative regulator of gene transcription, depending on the cell type (1, 26, 71) . Likewise, WT1 can act as a transcriptional activator in cells lacking p53 protein (43) . Thus, the cellular context determines the transcriptional regulatory functions of these DNA-binding proteins.
Functional studies, using stable transfection with effector constructs for ectopic expression of EGR-1 or antisense (AS) oligodeoxynucleotides for blockade of EGR-1 expression, have demonstrated that Egr-1 induction is essential for restricted differentiation along the macrophage lineage (49) . However, the precise function of Egr-1 in growth regulation is still unclear. Here, we present evidence that EGR-1 is induced in the growth arrest action of IL-1 and that inhibition of Egr-1 expression with an AS oligomer or competitive inhibition of Egr-1-dependent transactivation events with a dominant negative mutant leads to accelerated growth arrest by this cytokine. This study defines a novel regulatory role for Egr-1 in a growth arrest situation.
MATERIALS AND METHODS
Cell culture and cytokine. Human melanoma A375-C6 cells (22, 57) were grown in RPMI 1640 medium supplemented with 10% fetal bovine serum. Human recombinant IL-1␤ (specific activity, 1.8 ϫ 10 7 U/mg) was a gift from Craig Reynolds, Biological Response Modifiers Program, National Cancer Institute (Frederick, Md.).
Plasmid constructs. The expression plasmid for Egr-1, CMV-EGR1 (42), contains the full-length cDNA for Egr-1 placed under control of the cytomegalovirus promoter of vector pCB6 ϩ (42). The dominant negative mutant of Egr-1, CMV-WT1-EGR-1 (42), contains a WT1-Egr-1 chimera placed downstream of the cytomegalovirus promoter in pCB6
ϩ . The chimera contains the WT1 cDNA encoding amino acids 1 to 307, placed in frame upstream of the Egr-1 cDNA encoding amino acids 327 to 427 (42) . The WT1 domain of the construct provides the transrepression function to the chimera, while the EGR-1 domain which contains the three zinc fingers provides the DNA binding function (reference 42 and this study). The reporter construct, EBS-CAT (42), contains three EGR-1 binding sites (GCGGGGGCG) placed in tandem upstream of a minimal c-fos promoter and chloramphenicol acetyltransferase (CAT) cDNA. The construct containing the minimal c-fos promoter and CAT cDNA (42) is referred to as fos-CAT in this report.
DNA transfections. Cultures (0.5 ϫ 10 6 cells per 60-mm-diameter dish) were transfected with various DNA constructs mixed in N- [1-(2, 3-dioleoyloxy) propyl]-N,N,N-trimethyl-ammoniummethylsulfate (DOTAP) (at a final concentration of 5 g/ml; Boehringer Mannheim Biochemicals, Indianapolis, Ind.) for 18 h and then grown in fresh growth medium in the absence of DNA for an additional 24 h. The cells were then lysed by freeze-thawing, and protein concentrations were determined by using a colorimetric assay kit from Pierce Chemical Company (Rockford, Ill.). Appropriate amounts of the lysates were used to determine CAT activity by thin-layer chromatography as described previously (56) . Percent conversion of [ 14 C]chloramphenicol to acetylated forms was determined by excision of appropriate areas of the thin-layer chromatography plate and subjecting them to liquid scintillation counting. The values for percent conversion in different samples from a given experiment were normalized with respect to protein concentration and are expressed as relative CAT activity.
Immunocytochemistry. Cells (0.5 ϫ 10 6 /ml) were left untreated or exposed to IL-1 for various periods of time. In experiments in which the anti-IL-1R I antibody M1 or the anti-IL-1R II antibody M22 (from John Sims, Immunex, Seattle, Wash.) was used, the antibody was added to the culture medium at 5 g/ml 1 h prior to addition of IL-1. For experiments aimed at determining the specificity of the antiserum toward EGR-1, aliquots of the anti-EGR-1 antibody, sc-110, were preincubated with EGR-1 peptide that was used to raise the antibody or an unrelated EGR-2 peptide for negative control. About 2 g of peptide was preincubated at room temperature for 30 min with 1 l of antibody sc-110 in a total of 750 l of normal goat serum prior to use of the antibody for immunocytochemistry. In experiments aimed at blocking EGR-1 expression, we used a phosphorothioate-capped AS oligodeoxynucleotide (5Ј-TsGsCGGGGCGCGGG GAACAsCsT-3Ј [49] ) or, as a control, a phosphorothioate-capped nonsense (NS) oligodeoxynucleotide (5Ј-TsGsCTACTCGCGTCTAACAsCsT-3Ј), both purchased from Regional DNA Synthesis Laboratory (Calgary, Alberta, Canada). The AS oligomer was targeted against a 5Ј sequence located 119 to 100 bases upstream of the AUG initiation codon of human Egr-1. The oligodeoxynucleotides (at the indicated concentrations) were added to the cells 1 h prior to treatment with IL-1. After the appropriate treatments, the cells were fixed in 10% neutral buffered formalin and then incubated with H 2 O 2 for 30 min to block endogenous peroxidase activity. Next, the cells were incubated with antibody sc-110 (1:750 dilution in normal goat serum) or, as control, a preimmune rabbit antiserum (1:750 dilution in normal goat serum) for 18 h at 37ЊC in a humidified chamber. Reactions with biotinylated anti-rabbit immunoglobulin antibody, with avidin-biotin-peroxidase complexes, and with staining with diaminobenzidene-H 2 O 2 and counterstaining with methyl green were then sequentially performed as described in the Vectastain Elite ABC kit instruction manual (Vector Laboratories, Burlingame, Calif.).
Northern (RNA) analysis. Isolation of total RNA and Northern analysis were performed as described previously (10, 57) . The probe for Egr-1 was prepared with the 3.1-kb cDNA fragment from pCMV-EGR-1 (42) . For the WT1 probe, we used the 1.8-kb EcoRI fragment from cDNA clone WT33 (6) . Prehybridization and hybridization were done overnight at 62ЊC, and blots were washed to a final stringency of 0.1ϫ SSC (15 mM NaCl, 1.5 mM sodium citrate [pH 7]) at 62ЊC as described previously (57) . Equal loading of RNA was verified by probing blots with cDNA for glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and fold induction was calculated after densitometric scanning and normalization of the hybridization signal with respect to GAPDH. Assay for [ 3 H]thymidine incorporation. Incorporation studies were performed in 96-well plates, and percent growth inhibition was calculated as previously described (55) . In experiments aimed at determining which of the two IL-1Rs mediated the growth arrest action of IL-1, antibodies M1 (against IL-1R I and M22 (against IL-1R II ) were added to the cells at a final concentration of 5 g/ml at 1 h prior to addition of IL-1. In experiments in which the effect of the AS or NS oligomer on IL-1 action was tested, the cells were treated with the oligomer at 1 h prior to addition of the cytokine.
Flow cytometric analysis and cell cycle distribution. Cells (300,000 cells per 30 ml per T150 flask) were either left unexposed or exposed to IL-1 (100 U/ml) for 24, 48, or 72 h and prepared for flow cytometric assay after staining of the DNA with propidium iodide as described previously (4) . Flow cytometric analysis was performed in a fluorescence-activated cell sorting (FACS) apparatus (Becton Dickinson) by Richard Cross at the Flow Cytometry Core Facility, University of Kentucky. The number of cells in each compartment was obtained by using Modfit software (Verity Software, Topsham, Maine). The experiment was repeated four times, and at least 10,000 cells per sample were counted.
Western blot (immunoblot) analysis. Cells were left unexposed, exposed to IL-1 (100 U/ml) for 4 h, or exposed to IL-1R I antibody M1 (5 g/ml) or IL-1R II antibody M22 (5 g/ml) in the presence of IL-1 (100 U/ml) for 4 h. The antibodies were added 1 h before addition of IL-1 to the culture medium. Total cell extracts were electrophoresed on sodium dodecyl sulfate-7.5% polyacrylamide gels and transferred to nylon membranes as described previously (3) . The blots were incubated with blocking solution (5% nonfat milk in 10 mM Tris-Cl-150 mM NaCl) for 1 h, then probed for 18 h with EGR-1 antibody sc-110 (1 g/ml in blocking solution), and finally incubated with 125 I-protein A for 1 h. The same immunoblots (without stripping of the EGR-1 signal) were probed with anti-␤-actin antibody (Sigma Chemical Co., St. Louis, Mo.) at 1 g/ml. We have found that the levels of ␤-actin mRNA (57) and protein (48a) are unaltered in response to IL-1 in melanoma cells.
RESULTS

IL-1 causes induction of Egr-1.
We have previously described the isolation and identification of IL-1-inducible immediate-early genes, using differential screening of clones from a cDNA library which had been enriched by subtractive hybridization for IL-1 plus cycloheximide-inducible genes (55, 57) . When about 20,000 additional clones from the subtraction library were screened by differential hybridization (performed as described in reference 55), we isolated cDNAs representing a total of 14 different IL-1-plus-cycloheximide-inducible genes. Partial nucleotide sequencing of one of the cDNA clones revealed that it represented Egr-1/zif268/NGFI-A. However, our previous study (55) , which had used RNA from A375-C6 cells that were exposed to IL-1 for various periods of time up to 3 h, had suggested that Egr-1 is not induced by IL-1. We therefore performed Northern analysis with RNA from cells exposed to IL-1 for extended periods of time up to 24 h, using a cDNA probe for Egr-1, to ascertain that Egr-1 was indeed IL-1 induc-ible. As shown in Fig. 1a , low but detectable basal expression of Egr-1 was present in untreated cells. The gene was not induced within 2 h of exposure to IL-1 ( Fig. 1a ), but about fivefold induction was seen at 4 h. Thereafter, at 6 h of exposure to the cytokine, the level of induction dropped to about threefold, and by 24 h, the basal level of expression was attained (Fig. 1a) . These data suggest that Egr-1 is an IL-1-inducible gene in melanoma cells.
To determine whether Egr-1 induction is an immediate-early response to IL-1, Northern analysis was performed on RNA from A375-C6 cells that were left unexposed or exposed for 30 min to cycloheximide and further exposed for 4 h to cycloheximide alone or cycloheximide plus IL-1. As shown in Fig. 1b , Egr-1 levels were increased about 25-fold over basal levels upon treatment with cycloheximide alone. This is likely due to posttranscriptional stabilization of the preexisting Egr-1 mRNA in untreated A375-C6 cells as a result of inhibition of RNases by cycloheximide. Treatment with IL-1 in the presence of cycloheximide resulted in about 35-fold induction of Egr-1 (Fig. 1b) , suggesting that IL-1-inducible expression of this gene does not require de novo protein synthesis. Thus, Egr-1 induction is an immediate-early response to IL-1 in the melanoma cells.
To examine whether expression of EGR-1 protein correlated with the induction pattern of its RNA, we performed immunocytochemistry with an anti-EGR-1 antibody, sc-110. A375-C6 cells were exposed to IL-1 for various time intervals and then stained with sc-110 as described in Materials and Methods. EGR-1 was detected as a nuclear protein in cells that were left untreated ( Fig. 2a ; brown-stained nucleus indicated by arrowhead) as well as in those exposed to IL-1 (Fig. 2b) . Unexposed populations of A375-C6 cells contained Ͻ5% EGR-1-positive cells (Fig. 2d) . Upon exposure to IL-1, A375-C6 cultures did not show an increase in the number of EGR-1-positive cells at 1-and 2-h time points (data not shown). At 4 h of exposure to IL-1 (Fig. 2e) , the number of EGR-1-positive cells increased substantially over the number in the untreated population. Subsequently, at 6 h of exposure to IL-1 (Fig. 2f) , the number of EGR-1-positive cells gradually declined but was still higher than in untreated cultures. At 24 h of exposure to IL-1, the number of EGR-1-positive cells was similar to that seen in untreated populations (data not shown). In cultures exposed to IL-1 for 4 h, recognition of EGR-1 with the antibody was abrogated when immunostaining was performed with the EGR-1 antibody that had been preincubated with EGR-1 peptide (Fig. 2g) . On the other hand, preincubation with EGR-2 peptide did not affect the ability of the antibody to detect EGR-1 (data not shown), implying that the antibody specifically recognized EGR-1 protein. These data suggest that there exists a good correlation in the temporal pattern of induction of Egr-1 at the RNA and protein levels.
Both growth arrest and EGR-1 induction are mediated via IL-1R I . Although previous studies (13, 64) suggested that only IL-1R I can mediate IL-1 signaling, it was necessary to verify that this observation could be extended to the growth-inhibitory action of IL-1. Since one of the objectives of this study was to identify IL-1-inducible genes and then delineate their functional role in growth arrest, we began by examining whether growth arrest and Egr-1 induction are mediated via the same IL-1R. These experiments used anti-IL-1R monoclonal antibodies M1 and M22, which have been previously shown (64) to specifically block IL-1 binding to IL-1R I and IL-1R II , respectively. The effect of these antibodies on IL-1 growth arrest action was determined by [ 3 H]thymidine incorporation assays performed as described in Materials and Methods. In these studies, IL-1 (100 U/ml) caused 22% growth inhibition of A375-C6 cultures following exposure for 24 h (data not shown). However, when the cells were pretreated for 1 h with antibody M1 prior to IL-1 exposure, Ͻ5% of the cell population showed growth inhibition (data not shown). By contrast, in cells pretreated for 1 h with antibody M22, IL-1 showed 20% growth inhibition (data not shown). These data suggested that the growth-inhibitory action of IL-1 was mediated by IL-1R I .
To determine which of the two IL-1Rs mediated IL-1-inducible EGR-1 induction, we performed immunocytochemistry on A375-C6 cultures exposed to IL-1 (100 U/ml) after pretreatment for 1 h with antibody M1 or M22. As shown in Fig. 2h , pretreatment with antibody M22 did not inhibit the increase in the number of EGR-1-positive cells upon exposure for 4 h to IL-1. On the other hand, preexposure to antibody M1 abrogated the IL-1-inducible increase in the number of EGR-1-positive cells (Fig. 2i) .
We also performed Western blot analysis on protein extracts from A375-C6 cells that were left untreated or treated with IL-1 in the presence or absence of antibodies M1 or M22. The anti-EGR-1 antibody, sc-110, mainly reacted with an 80-kDa protein (EGR-1) in extracts from untreated cells (Fig. 3) . The molecular size of this protein is consistent with that reported in other cell types (7) for EGR-1. The expression of EGR-1 was strongly induced by IL-1 (Fig. 3) . Two other relatively weak bands were also detected ( Fig. 3) : (i) a 110-kDa band, whose intensity was unaltered by the various treatments, which most likely represents a protein reacting nonspecifically with the antibody; and (ii) a 65-kDa band, probably a product of alternative usage of start codon, premature termination, or degradation. The presence of antibody M1 inhibited the ability of IL-1 to induce EGR-1 (Fig. 3) . By contrast, IL-1-inducible FIG. 1. IL-1 causes immediate-early induction of Egr-1. A375-C6 cells were left untreated (UT) or treated with IL-1 (100 U/ml) for various intervals of time, as indicated (a). To determine whether Egr-1 induction by IL-1 is an immediateearly response, the cells were left untreated (UT) or preexposed to cycloheximide (CHX; 20 g/ml) for 30 min to block new protein synthesis before exposure for 4 h to cycloheximide alone (20 g/ml) or cycloheximide plus IL-1 (b). RNA was then prepared from these cells and subjected to Northern analyses using Egr-1 and GAPDH cDNA probes. expression of EGR-1 was not inhibited in the presence of antibody M22 (Fig. 3) . When the same blot was reprobed, without stripping of the EGR-1 signal, with an anti-␤-actin antibody, expression of ␤-actin was found to be unaltered by the various treatments (Fig. 3) . Together, these results suggest that the same receptor, IL-1R I , mediates both IL-1-inducible growth arrest and EGR-1 induction. Dominant negative mutant of Egr-1 inhibits Egr-1-dependent transcriptional activation via the GC-rich binding sequence. In NIH 3T3 fibroblast cells, an EGR-1 expression plasmid construct, CMV-EGR1, has been shown (42) to transactivate a CAT reporter plasmid construct, EBS-CAT, which contains three tandem EGR-1 binding sites. Transactivation by EGR-1 is inhibited by cotransfection with plasmid construct CMV-WT1-EGR1, which expresses a chimeric protein consisting of the transrepression domain of the Wilms' tumor gene product, WT1, and the three zinc fingers of EGR-1. Thus, plasmid construct CMV-WT1-EGR1 functions as a dominant negative mutant of Egr-1 in the fibroblast cells (42) . To determine whether this construct could be used as a dominant negative inhibitor of EGR-1 function in melanoma cells, we first ascertained that EGR-1 expressed by construct CMV-EGR1 could cause transactivation of EBS-CAT in A375-C6 cells. The cells were transiently transfected with plasmid EBS-CAT and different amounts of plasmid CMV-EGR1. The total amount of plasmid DNA was adjusted to 36 g with vector pCB6
ϩ DNA. As seen in Fig. 4a , cells cotransfected with plasmid EBS-CAT and pCB6 ϩ empty vector (i.e., 0 g of CMV-EGR1) showed low-background-level CAT activity. Upon cotransfection with CMV-EGR1, CAT activity from plasmid EBS-CAT markedly increased in a dose-dependent manner: up to 8 g of plasmid CMV-EGR1 was used, and this amount showed about a 10-fold increase in CAT activity over that seen in the absence of CMV-EGR1. Induction of CAT activity required the presence of the EGR-1 binding sites, because the minimal c-fos promoter construct, fos-CAT, lacking these sites, did not show CAT induction upon cotransfection with up to 8 g of plasmid CMV-EGR1 (Fig. 4a) .
We next examined whether construct CMV-WT1-EGR1 competitively inhibited the ability of plasmid CMV-EGR1 to cause induction of CAT activity from reporter construct EBS-CAT. In triple-transfection experiments with constant amounts of plasmids EBS-CAT (4 g) and CMV-EGR1 (4 g) and different amounts of (i.e., 8, 16 , and 24 g) plasmid CMV-WT1-EGR1, we found that plasmid CMV-WT1-EGR1 inhibited EGR-1-mediated transactivation in a dose-dependent fashion (Fig. 4a) . In control transfection experiments with plasmids CMV-EGR1, CMV-WT1-EGR1, and fos-CAT, plasmid CMV-WT1-EGR1 did not alter the low-level CAT activity of the reporter plasmid fos-CAT, indicating that the EGR-1 binding sequence was necessary for transactivation by plasmid CMV-EGR1 and competitive inhibition of that transactivation by plasmid CMV-WT1-EGR1 (Fig. 4a) . In another control transfection experiment which used plasmid EBS-CAT (4 g), plasmid CMV-EGR1 (4 g), and different amounts of pCB6 ϩ (up to 24 g), pCB6
ϩ did not affect the ability of plasmid CMV-EGR1 to transactivate CAT (data not shown). Thus, the WT1-EGR-1 chimera can inhibit EGR-1 (i.e., expression plasmid CMV-EGR1)-dependent transactivation of EBS-CAT, suggesting that the chimera functions as a dominant negative mutant in A375-C6 cells.
Cell lines expressing the dominant negative mutant of Egr-1 inhibit EGR-1-dependent transactivation. To study the effect of the dominant negative mutant on IL-1 action, we transfected A375-C6 cells with plasmid CMV-WT1-EGR1 or, a control, an empty vector (pCB6 ϩ ) and obtained stable transfectant cell lines by selection with G418 sulfate. A total of four different A375-C6/WT1-EGR1 cell lines (i.e., A375-C6 cells containing plasmid CMV-WT1-EGR1) and two different A375-C6/Vector cell lines (i.e., A375-C6 cells containing empty vector pCB6 ϩ ) were studied. To ascertain that the A375-C6/WT1-EGR1 cell lines constitutively expressed the chimeric transcript, total RNA was prepared from the transfectant cell lines, and Northern analysis was performed with the 1.8-kb EcoRI fragment of WT33 cDNA (6) as a probe for WT1. This DNA fragment contains the region corresponding to the transrepression domain and all four zinc fingers of WT1. Data for two of the A375-C6/WT1-EGR1 cell lines and two of the A375-C6/Vector cell lines are shown in Fig. 5 . A375-C6/ WT1-EGR1 cell lines L1 and L4 expressed the 1.2-kb transcript corresponding to the 397 amino acid residues (42) of the WT1-EGR-1 chimera (Fig. 5a) . The A375-C6/Vector control cell lines, L1 and L2, did not express the 1.2 kb-chimeric transcript (Fig. 5a) . Interestingly, the WT1 probe hybridized to a 0.9-kb transcript in all of the cell lines (Fig. 5a) ; this transcript might represent another, as yet uncharacterized member of the Egr family, an alternatively spliced form of WT1, or an unrelated cross-hybridizing RNA species. The same blot was probed with GAPDH, and Fig. 5b shows the GAPDH signal and residual 0.9-kb signal.
To ascertain that IL-1R I function was not compromised in the A375-C6/WT1-EGR1 cell lines, we exposed these cells to IL-1 and performed immunocytochemistry using the anti-EGR-1 antibody sc-110 to determine gene expression. Since the anti-EGR-1 antibody was raised against 14 amino acids at the absolute carboxy terminus of EGR-1 and this region was absent in the chimeric protein, we did not expect the anti-EGR-1 antibody to react with the chimeric protein. Immunocytochemistry revealed that EGR-1 protein was expressed in Ͻ5% of untreated A375-C6/WT1-EGR1.L4 cells (Fig. 2j) but was induced in cells exposed to IL-1 for 4 h (Fig. 2k) . Similar to findings for the parental cells, immunostaining localized EGR-1 to the nucleus in these transfected cells ( Fig. 2c ; only the IL-1-treated cells are shown). Moreover, immunocytochemistry revealed that induction of EGR-1 by IL-1 in the A375-C6/WT1-EGR1.L4 cell line was inhibited by antibody M1 but not antibody M22 (data not shown), indicating that similar to findings for the parental nontransfected cell line, IL-1 induced gene expression in the transfected cells via IL-1R I and not IL-1R II . We also performed Northern analysis on A375-C6/WT1-EGR1.L4 cells that were left unexposed or exposed to IL-1 for different intervals of time. These experiments revealed that when exposed to IL-1, A375-C6/WT1-EGR1.L4 cells showed Egr-1 induction with kinetics similar to those seen in A375-C6 cells (data not shown).
We next determined whether A375-C6/WT1-EGR1 cell lines contained a functional dominant negative mutant of Egr-1 by assaying for transactivation of EBS-CAT by construct CMV-EGR1. Four different A375-C6/WT1-EGR1 cell lines (L1, L2, L4, and L13) and two different A375-C6/Vector cell lines (L1 and L2) were examined in this manner, and representative data are shown in Fig. 4b . Cotransfection of A375-C6/WT1-EGR1 or A375-C6/Vector cell lines with EBS-CAT reporter construct and different concentrations of plasmid CMV-EGR1 revealed that up to 8 g of CMV-EGR1 failed to induce CAT activity in A375-C6/WT1-EGR1 cells (Fig. 4b) . By contrast, in the control A375-C6/Vector cell lines, 2 g of CMV-EGR1 was sufficient to drive CAT activity (Fig. 4b) . These data indicated that in A375-C6/WT1-EGR1 transfectant cell lines, EGR-1-dependent transactivation via the EGR-1 binding site is inhibited by the dominant negative chimera.
The dominant negative mutant of EGR-1 accelerates IL-1-induced growth arrest. We have previously shown by [ (Fig. 6a) , which are representative of all of the cell lines, suggested that the growth rates of A375-C6/WT1-EGR1 cell lines were similar to those of A375-C6/Vector cell lines. This meant that the dominant negative mutant did not alter the growth rate of the host cells. Upon treatment with IL-1 (100 U/ml), the A375-C6/Vector cell lines showed about 20, 50, and 80% growth inhibition in 24, 48, and 72 h, respectively (Fig.  6b) . By contrast, A375-C6/WT1-EGR1 cells generally showed increased inhibition in response to IL-1: about 50, 80, and 85% (22, 55, 55a, 57, 72) . The remaining 15 to 20% of cells appear to be phenotypically (and not genotypically) resistant to IL-1 under the experimental conditions used, because upon replating, about 80 to 85% of this population shows susceptibility to the cytokine (55a). The chimera seems, therefore, to accelerate the inhibitory response in cells that are potentially susceptible to IL-1 but not in those that are resistant. We next examined whether cells transfected with the dominant negative mutant construct showed enhanced sensitivity to different doses of IL-1. Cells were exposed to different concentrations of IL-1 for 24 h, and incorporation of [ 3 H]thymidine into DNA was determined. Four different A375-C6/WT1-EGR1 cell lines (L1, L2, L4, and L13) and two different A375-C6/Vector cell lines (L1 and L2) were studied, and representative data are shown in Fig. 6c . A375-C6/WT1-EGR1 cells showed about 30% growth inhibition upon 24 h of exposure to 5 U of IL-1 per ml. At this concentration of IL-1, A375-C6/Vector cells did not show detectable inhibition in 24 h. Similarly, at all the other concentrations of IL-1 (25, 50, or 100 U/ml), A375-C6/WT1-EGR1 cells showed higher inhibition (P Ͻ 0.001 by the Student t test) than did A375-C6/Vector cells (Fig. 6c) . These data suggested that the dominant negative mutant of Egr-1 renders the melanoma cells supersensitive to IL-1 and accelerates the growth-inhibitory response to the cytokine.
Previous studies (22, 55a) have shown that the action of IL-1 in A375-C6 cells is reversible upon reseeding the cells in IL-1-free growth media, implying that IL-1 causes growth arrest and not death in these cells. To determine whether IL-1 caused growth arrest of the melanoma cells in any particular phase of the cell cycle, we performed FACS analysis on propidium iodide-stained cultures of A375-C6/WT1-EGR1.L4 and A375-C6/Vector.L1 cell lines exposed to IL-1. In unexposed populations, the distributions of cells in various phases of the cycle over the 3-day test period were comparable in A375-C6/Vector.L1 cells and A375-C6/WT1-EGR1.L4 cells, and the total number of cells in G 0 /G 1 never exceeded 60% (Fig. 7a) . Exposure of A375-C6/Vector.L1 cells to IL-1 resulted in a gradual increase in the number of cells accumulating in G 0 /G 1 , with a concomitant decrease in the number of cells in S and G 2 ϩM phases of the cell cycle (Fig. 7b) . A375-C6/WT1-EGR1.L4 cells (Fig. 7b) , on the other hand, showed accelerated accumulation (statistically significant difference for 24-and 48-h time points by the Student t test, P Ͻ 0.001) in the G 0 /G 1 phase upon exposure to IL-1 and a concomitant rapid drop in the number of cells in the S phase (difference statistically significant for 24-and 48-h time points, P Ͻ 0.001) and G 2 ϩM phase (difference not statistically significant, P ϭ 0.01). These data suggest that exposure to IL-1 results in a G 0 /G 1 block in cell cycle progression causing a decrease in the number of S phase cells and corroborate our observation of enhanced IL-1 susceptibility in cells expressing the dominant negative mutant.
The AS Egr-1 oligomer accelerates IL-1-induced growth arrest. Since Egr-1 belongs to a family of multiple genes encoding zinc finger transcription factors that regulate gene expression via the same DNA binding sequence, it was plausible that in the transfected cell lines, the dominant negative mutant competed with the transactivation function of other members of the Egr family. The enhanced susceptibility of A375-C6/WT1-EGR1 cell lines to IL-1 could therefore be a result of competitive inhibition of the transactivation function of another member of the Egr family and not EGR-1 itself. To address this question, we used an AS oligodeoxynucleotide that has been previously shown (49) to block Egr-1 expression. An NS oligodeoxynucleotide was included in the study as a control. [ 3 H]thymidine uptake studies revealed that the maximal amount of the AS oligomer that did not cause growth inhibition on its own in A375-C6/Vector.L1 or A375-C6/WT1-EGR1.L4 cells was 20 M, whereas that for the NS oligomer was 25 M (data not shown). Next, we performed immunocytochemistry using the anti-EGR-1 antibody sc-110 on A375-C6/Vector.L1 or A375-C6/WT1-EGR1.L4 cells that were pretreated with these concentrations of the NS or AS oligomer and exposed to IL-1 for 4 h. Data for A375-C6/Vector.L1 cells are shown in Fig. 2l to o) . Untreated A375-C6/Vector.L1 cultures showed Ͻ5% EGR-1-positive cells (Fig. 2l) , whereas exposure to IL-1 led to an increase in the number of EGR-1-positive cells (Fig. 2m) . Furthermore, NS oligomer treatment (Fig. 2n) did not affect EGR-1 induction by IL-1, whereas the AS oligomer inhibited this induction (Fig. 2o) . Similarly, the AS oligomer but not the NS oligomer inhibited IL-1-inducible expression of EGR-1 in A375-C6/WT1-EGR1.L4 cells (data not shown). Thus, the AS oligomer could block IL-1-inducible expression of EGR-1 in the transfectant cell lines.
To determine the effect of the AS oligomer on IL-1-inducible growth inhibition, we performed [ 3 H]thymidine incorporation experiments. When A375-C6/Vector.L1 or A375-C6/ WT1-EGR1.L4 cell lines were preincubated with the AS or NS oligomer for 1 h and then exposed to IL-1 (100 U/ml) for 24 or 48 h, we found that NS oligomer-treated A375-C6/Vector cells showed about 25 and 50% growth inhibition in 24 and 48 h, respectively (Fig. 8a) . By contrast, the AS oligomer-treated A375-C6/Vector cells showed about 50 and 80% growth inhibition in 24 and 48 h, respectively (Fig. 8a) . In the presence of the NS oligomer, A375-C6/WT1-EGR1 cells showed 50 and 80% inhibition in response to IL-1 in 24 and 48 h, respectively, as expected (Fig. 8a) . However, these cells did not show a further increase in inhibition when treated with IL-1 plus the AS oligomer (Fig. 8a) . Statistical evaluation of the data in Fig.  8a by the Student t test indicated that the difference between the response of A375-C6/Vector cells to the AS oligomer plus IL-1 versus the NS oligomer plus IL-1 was significant (P Ͻ 0.001).
We next performed [ 3 H]thymidine incorporation studies to determine whether pretreatment with the AS oligomer rendered the cells sensitive to low concentrations of IL-1. At a concentration of 5 U of IL-1 per ml, no detectable inhibition was seen in NS oligomer-treated A375-C6/Vector.L1 cells, whereas about 35% inhibition was seen in AS oligomer-treated A375-C6/Vector.L1 cells in 24 h (Fig. 8b) . These data indicate that AS oligomer-mediated inhibition of Egr-1 results in sensitization of the cells to IL-1-induced growth arrest. The A375-C6/WT1-EGR1.L4 cells showed about 30% inhibition with IL-1 in the presence of the NS oligomer (Fig. 8b) . Most importantly, the AS Egr-1 oligomer did not cause a further increase in the susceptibility of A375-C6/WT1-EGR1.L4 cells to IL-1 (Fig. 8b) , suggesting that the enhanced sensitivity of these 
DISCUSSION
This study demonstrates that IL-1 action in human melanoma cells is associated with induction of Egr-1 at both the RNA and protein levels. Transfection studies revealed that the Egr-1 gene product acted as a positive modulator of reporter gene transcription in melanoma cells. Inhibition of EGR-1 function with a dominant negative mutant or Egr-1 expression with an AS oligomer resulted in an enhanced and accelerated growth arrest response to IL-1. These data suggest that EGR-1 serves as a negative modulator of IL-1-induced growth inhibition in melanoma cells. EGR-1 is also induced by serum growth factors in these cells (48a, 57) . However, neither the dominant negative mutant nor the AS oligomer was found to alter the mitogenic response to serum in these cells (48a) . This apparent EGR-1-independent mitogenic response to serum suggests that EGR-1 is a dispensable component of the mitogenic pathway. An alternate explanation is that serum, which is a mixture of growth factors, induces multiple gene pathways, and one or more of the gene products may circumvent and override the block in EGR-1 function. By contrast, the fact that abrogation of Egr-1 expression results in acceleration of IL-1 action implies that EGR-1 is an indispensable component of the IL-1 signaling pathways and that EGR-1 serves a key function to counteract the growth-inhibitory signals elicited by the cytokine.
The association of Egr-1 with a growth arrest signal is particularly interesting because this gene was originally identified in growth-stimulatory situations (68), and we have previously shown that Egr-1 is induced by serum, a mitogenic agent, in A375-C6 cells (55) . Although these facts suggested that Egr-1 is not a growth arrest-specific gene, we pursued the functional role of this gene in IL-1 action for the following reasons: (i) in this study, we found that both the growth arrest action and Egr-1 induction were signaled by IL-1 via the same IL-1R (IL-1R I ), suggesting that Egr-1 may play a role in transducing growth-inhibitory signals; and (ii) we (55, 62) and others (18, 23, 63) have shown that agents which cause growth inhibition often induce gene programs that overlap the growth-stimulatory programs induced by mitogenic agents in the same cell type, suggesting that such overlapping genes, particularly those encoding multifunctional transcription factors such as c-jun, c-fos, c-myc, and Egr-1, may play inducer-specific roles in growth control. Since Egr-1 is also induced by serum growth factors in melanoma cells, Egr-1 induction by IL-1 in these cells provided an excellent model system with which to determine whether this gene played distinct phenotypic roles dependent on whether it was induced as part of a growth-inhibitory or -stimulatory cascade. Furthermore, understanding the function of Egr-1 was important because this gene is induced during diverse activator-driven phenotypic alterations including growth, differentiation, and development (66) (67) (68) .
To study the functional role of Egr-1 in IL-1-induced growth arrest, we utilized a WT1-EGR-1 chimera to compete functionally with endogenous EGR-1. We reasoned that if Egr-1 was critical for the biological effect of IL-1, a block in its function or expression in this manner would abrogate growth arrest. Transient expression assays in the melanoma cells revealed that the chimera inhibited EGR-1-driven transactivation of reporter construct containing EGR-1 binding sites upstream of the minimal c-fos promoter. Furthermore, cell lines which stably expressed the chimera did not show transactivation of the reporter construct when cotransfected with the EGR-1 effector plasmid, suggesting that the chimera acted as a dominant negative mutant in melanoma cells. The chimera might function as a dominant negative mutant by competing with endogenous EGR-1 protein for binding to the GC-rich sites in the regulatory regions of various target genes and further by transrepression of those genes. The dominant negative mutant did not alter the growth characteristics of the host cell, as evident from the facts that the growth rates and cell cycle distributions of the cell lines stably transfected with the chimera were similar to those of the parental cell lines transfected with an empty vector for a control. Furthermore, the chimera did not alter the number of IL-1Rs on its host A375-C6 cells: receptor binding studies and Scatchard analysis indicated that cells transfected with the vector had 701 Ϯ 102 receptors per cell, and those transfected with the chimera had 617 Ϯ 69 receptors per cell (48a). The cell lines expressing the dominant negative mutant were therefore ideal for studying the effect of functional inhibition of EGR-1 on IL-1 action in the melanoma cells.
Inducible genes may serve to mediate the cause of the phenotypic changes signaled by the inducer or, on the other hand, may play cellular defense roles to counteract, dampen, or balance the impact of the inducer. Alternately, gene induction may constitute an epiphenomenon and not necessarily serve a function in the ultimate phenotypic change brought about by the activator. In cultured cells, some inducible genes may represent vestigial functions carried over form the natural tissue setting in the host, where they may play important biological roles. With these different possibilities in mind, the function of IL-1-inducible Egr-1 expression was examined in melanoma cells. This study revealed that cell lines expressing the dominant negative mutant showed accelerated inhibition in response to IL-1. Furthermore, a low concentration (5 U/ml) of IL-1, which was otherwise noninhibitory for the parental cells or for those transfected with the empty vector, caused growth inhibition in the cells expressing the chimera. Consistent with this observation, we found that IL-1 caused accelerated G 0 /G 1 growth arrest in cells expressing the chimera. These data suggested that inhibition of EGR-1 function by the chimera conferred an IL-1-supersensitive phenotype upon the melanoma cells. Since the chimera was expected to inhibit the function of other members of the Egr family, we used an AS Egr-1 oligomer to determine whether the accelerated growth inhibition in the cells expressing the chimera was due to competition specifically with Egr-1. These studies indicated that the AS oligomer and not the control NS oligomer rendered the A375-C6/Vector cells supersensitive to IL-1 and caused accelerated growth arrest. By contrast, in cells expressing the chimera, the AS oligomer did not further accelerate the growth arrest response to IL-1. Most importantly, sensitivity to IL-1 in cells treated with the AS oligomer was comparable to that in cells expressing the chimera. These results imply that the increased sensitivity to IL-1 in cells expressing the chimera was due to competition with EGR-1. By inference, therefore, the role of EGR-1 in the melanoma cells is to impede IL-1-induced phenotypic alterations that include growth inhibition in the G 0 /G 1 phase.
Simultaneous induction/activation of effectors that cause a particular response and antieffectors that downmodulate the response is well documented. A few examples of coinduced or coactivated molecules with antiparallel effects are the transcriptional activator NF-B and its inhibitor MAD-3/IB (70) and the mitogen-activated protein kinase kinases that phosphorylate mitogen-activated protein kinase and MKP-1/ERP phosphatase that inhibits this activation (50, 69 (28) , and the platelet-derived growth factor A-chain gene (71) . Identification of the gene(s) whose regulation by EGR-1 impedes IL-1 action is the focus of our ongoing studies in melanoma cells. Furthermore, since IL-1 is a mitogenic signal for other transformed or nontransformed cell types (22, 55, 57) , these studies can be extended to examine whether EGR-1 serves also as an indispensable component of growth stimulation by the cytokine.
